Critique of Apixaban Versus Warfarin in Patients With Atrial Fibrillation

被引：2
|
作者：
Nedeltchev, Krassen [1 ,2 ]
机构：
[1] Triemli Hosp, Dept Neurol, CH-8063 Zurich, Switzerland
[2] Univ Bern, Bern, Switzerland
来源：
STROKE | 2012年 / 43卷 / 03期
关键词：
anticoagulation; apixaban; atrial fibrillation; DABIGATRAN;
D O I：
10.1161/STROKEAHA.111.640961
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：922 / 923
页数：2
相关论文
共 50 条
  • [21] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [22] ARISTOTLE reveals superiority of apixaban over warfarin in patients with atrial fibrillation
    Bryony M. Mearns
    Nature Reviews Cardiology, 2011, 8 (11) : 607 - 607
  • [23] Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy
    Mentias, Amgad
    Heller, Eric
    Vaughan Sarrazin, Mary
    STROKE, 2020, 51 (07) : 2076 - 2086
  • [24] Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
    Altawalbeh, Shoroq M.
    Alshogran, Osama Y.
    Smith, Kenneth J.
    VALUE IN HEALTH, 2018, 21 (12) : 1365 - 1372
  • [25] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Athanasakis, Kostas
    Boubouchairopoulou, Nadia
    Karampli, Eleftheria
    Tarantilis, Filippos
    Savvari, Paraskevi
    Bilitou, Aikaterini
    Kyriopoulos, John
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) : 123 - 133
  • [26] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [27] Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study
    Avezum, A.
    Lopes, R. D.
    Schulte, P. J.
    Lanas, F.
    Hanna, M.
    Pais, P.
    Erol, C.
    Diaz, R.
    Granger, C. B.
    Alexander, J. H.
    EUROPEAN HEART JOURNAL, 2013, 34 : 809 - 809
  • [28] COST CONSEQUENCE ANALYSIS OF APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE MEXICAN PUBLIC HEALTH SECTOR
    Juarez-Garcia, A.
    Donato, B. M. K.
    Mucino-Ortega, E.
    Davila, A.
    Guirant-Corpi, L.
    VALUE IN HEALTH, 2014, 17 (03) : A109 - A109
  • [29] ARISTOTLE: Apixaban versus warfarin versus Auricular Fibrillation
    Garcia Caballero, R.
    REVISTA CLINICA ESPANOLA, 2012, 212 (04): : 208 - 208
  • [30] Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial
    Focks, Jeroen Jaspers
    Brouwer, Marc A.
    Wojdyla, Daniel M.
    Thomas, Laine
    Lopes, Renato D.
    Washam, Jeffrey B.
    Lanas, Fernando
    Xavier, Denis
    Husted, Steen
    Wallentin, Lars
    Alexander, John H.
    Granger, Christopher B.
    Verheugt, Freek W. A.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
12345